Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging.
Magneto-fluorescent silica nanoparticles were conjugated with cetuximab for the targeting and imaging of colon cancer. In this study, cetuximab-conjugated magneto-fluorescent nanoparticles (MFSN-Ctx) could specifically target colon cancer cells that expressed EGFR on their cell membranes, and specific fluorescence was detected. MFSN-Ctx produced significant MRI signal changes in a human colon cancer xenograft mouse model. Intravenous injection of MFSN-Ctx resulted in faster uptake as compared to intraperitoneal injection, indicating that MFSN-Ctx had different kinetic properties in tumors based on the method of injection. The local concentration of MFSN-Ctx in a tumor was amplified by the use of an external magnetic field. These results demonstrate the potential application of MFSN-Ctx for the detection of EGFR-expressing colon cancer using in vivo imaging approaches.
Cho
Young-Seok
YS
Department of Internal Medicine, The Catholic University of Korea, 505, Banpo-dong, Seoul 137701, Republic of Korea.
Yoon
Tae-Jong
TJ
Jang
Eue-Soon
ES
Soo Hong
Kwan
K
Young Lee
Shin
S
Ran Kim
Ok
O
Park
Cheongsoo
C
Kim
Yong-Jin
YJ
Yi
Gyu-Chul
GC
Chang
Kiyuk
K
D000818:Animals; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D045744:Cell Line, Tumor; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000737:chemistry / Q000175:diagnosis*; D066246:ErbB Receptors / Q000032:analysis; D005453:Fluorescence; D006801:Humans; D008279:Magnetic Resonance Imaging; D008280:Magnetics; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles; D012822:Silicon Dioxide
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D012822:Silicon Dioxide; D066246:ErbB Receptors; D000068818:Cetuximab